Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer
For premenopausal women receiving ovarian suppression, risk for breast cancer recurrence reduced with aromatase inhibitor versus tamoxifen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 11, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer
FRIDAY, Feb. 11, 2022 -- For premenopausal women with estrogen receptor (ER)-positive breast cancer receiving ovarian suppression, use of an aromatase inhibitor rather than tamoxifen is associated with a reduced risk for recurrence, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 11, 2022 Category: Pharmaceuticals Source Type: news
Oncotarget: Phase 1 study of Z-Endoxifen in patients with solid tumors
(Impact Journals LLC) The Oncotarget article provides evidence that antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2021 Category: Cancer & Oncology Source Type: news
Could Tamoxifen Dose Be Slashed Down to 2.5 mg? Could Tamoxifen Dose Be Slashed Down to 2.5 mg?
Adherence to tamoxifen is notoriously low because of troublesome side effects. Could a substantially lower dose be used instead?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Lower dose of oestrogen receptor modulator seems to reduce risk of breast cancer
(Karolinska Institutet) While the drug tamoxifen reduces the risk of developing breast cancer and prevents recurrence, the side-effects cause many women to discontinue their treatment. A study involving researchers at Karolinska Institutet in Stockholm has now found that a much lower dose than the standard produces a good effect with fewer adverse reactions in women who have yet to enter the menopause. The study, which has been published in theJournal of Clinical Oncology, can play a significant role in the treatment of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2021 Category: Cancer & Oncology Source Type: news
Tamoxifen-related NAFLD: Prevalence, Incidence, Risk Factors Tamoxifen-related NAFLD: Prevalence, Incidence, Risk Factors
How common is the development of fatty liver after tamoxifen treatment in breast cancer patients, and what are the associated risk factors?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Estrogen may facilitate the growth of liver metastases in non-sex-specific cancers
(McGill University Health Centre) A study led by Dr. Pnina Brodt shows that the liver immune microenvironment reacts to metastatic cells differently in male and that in female mice and estrogen can indirectly contribute to the growth of metastases. These findings provide a rationale for further exploration of the role of sex hormones in female cancer patients and the potential benefits of anti-estrogen drugs such as tamoxifen in the treatment of hormone-independent cancers that metastasize to the liver. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2020 Category: International Medicine & Public Health Source Type: news
TP53 Status as Determinant of ESR2 Effects in Breast Cancer TP53 Status as Determinant of ESR2 Effects in Breast Cancer
Therapeutic modification of the mutant TP53-ESR2 interaction with agents such as tamoxifen may offer promise for triple negative breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women
(Queen Mary University of London) The Queen Mary University of London professor leading an international breast cancer study says anastrozole -- rather than tamoxifen -- should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2019 Category: Cancer & Oncology Source Type: news
‘No Longer a Disease for Our Moms and Grandmas’: Women on Early Breast Cancer
After a Styles column about one woman ’s experience with an early diagnosis, readers shared poignant stories of fear and survival. (Source: NYT Health)
Source: NYT Health - November 8, 2019 Category: Consumer Health News Authors: Aidan Gardiner Tags: Breast Cancer Mastectomy Radiation Mammography Tamoxifen (Drug) New York Times Source Type: news
Discussing medication therapies that can help prevent breast cancer in high risk patients
The goal of preventive medications is to reduce the risk of developing breast cancer. "The data shows about a 50-60 % reduction in risk," says Dr. Sandhya Pruthi, a Mayo Clinic internal medicine physician and breast cancer expert. Dr. Pruthi's research interests include chemoprevention of breast cancer using selective estrogen receptor modulators, such as tamoxifen [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 2, 2019 Category: Databases & Libraries Source Type: news
New Support for Ovarian Suppression with Endocrine Therapy in Premenopausal Breast Cancer
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor –positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Ovarian Suppression Combined with Tamoxifen May Help Premenopausal Patients
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor –positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 25, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Update of this US guidance now includes anastrazole as an option in postmenopausal women at increased risk. Tamoxifen 20 mg/day for 5yrs is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 5, 2019 Category: Consumer Health News Source Type: news
